Please use this identifier to cite or link to this item: http://dspace.mediu.edu.my:8181/xmlui/handle/123456789/5982
Full metadata record
DC FieldValueLanguage
dc.creatorErik Alsegård-
dc.date2004-
dc.date.accessioned2013-05-30T13:57:47Z-
dc.date.available2013-05-30T13:57:47Z-
dc.date.issued2013-05-30-
dc.identifierhttp://www.law.ed.ac.uk/ahrb/script-ed/docs/doha.asp-
dc.identifierhttp://www.doaj.org/doaj?func=openurl&genre=article&issn=17442567&date=2004&volume=1&issue=1&spage=12-
dc.identifier.urihttp://koha.mediu.edu.my:8181/jspui/handle/123456789/5982-
dc.descriptionThe purpose of this article is to analyse how developments after the Doha Declaration went wrong; how developing countries can best be helped by IPR legislation; and whether such help can be achieved without taking away the incentives for industry to develop medicines. It is submitted that a legal framework maintaining the global protection of IPRs is needed, especially in developed countries, but that such a framework must allow for compulsory licensing in separate, regional generic markets , and must further create effective barriers for (re-)import into other countries than those targeted by the compulsory licence. This proposal would create a large market currently unused, in which pharmaceuticals could be produced and sold more cheaply, while protecting developed countries from importation of generic drugs. This way, compulsory licensing should work as a tool to promote innovation whilst also protecting public health globally.-
dc.publisherAHRB Research Centre for Studies in Intellectual Property and Technology Law-
dc.sourceSCRIPT-ed-
dc.subjectDoha-
dc.subjectacces to medicines-
dc.subjectpatents-
dc.subjectpharmaceuticals-
dc.titleGlobal pharmaceutical patents after the Doha Declaration What lies in the future?-
Appears in Collections:Law and Political Science

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.